消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量

2018-04-10 北美小儿胃肠病、肝脏病和营养学会 J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):680-6

炎症性肠病生物制剂

2018年4月，北美小儿胃肠病、肝脏病和营养学会(NASPGHAN)发布了关于确保儿童炎症性肠病非住院患者生物制剂输注质量的临床报告，文章主要目的是针对家庭和门诊输注生物药剂治疗的儿童炎症性肠病患者提供8条指导建议，从而确保治疗效果。

中文标题：

2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量

英文标题：

Assuring Quality for Non-hospital–based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

发布机构：

北美小儿胃肠病、肝脏病和营养学会

发布日期：

2018-04-10

简要介绍：

2018年4月，北美小儿胃肠病、肝脏病和营养学会(NASPGHAN)发布了关于确保儿童炎症性肠病非住院患者生物制剂输注质量的临床报告，文章主要目的是针对家庭和门诊输注生物药剂治疗的儿童炎症性肠病患者提供8条指导建议，从而确保治疗效果。

 

拓展指南：与炎症性肠病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量)] GetToolGuiderByIdResponse(projectId=1, id=ce80a1c0015828af, title=2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量, enTitle=Assuring Quality for Non-hospital–based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, guiderFrom=J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):680-6, authorId=null, author=, summary=2018年4月，北美小儿胃肠病、肝脏病和营养学会(NASPGHAN)发布了关于确保儿童炎症性肠病非住院患者生物制剂输注质量的临床报告，文章主要目的是针对家庭和门诊输注生物药剂治疗的儿童炎症性肠病患者提供8条指导建议，从而确保治疗效果。 , cover=, journalId=null, articlesId=null, associationId=99, associationName=北美小儿胃肠病、肝脏病和营养学会, associationIntro=北美小儿胃肠病、肝脏病和营养学会（North American Society for Pediatric Gastroenterology, Hepatology and Nutrition，NASPGHAN）有1400多成员组成，其主要分布在美国、哥伦比亚、波罗黎各、墨西哥和加拿大等国。 其专注于儿童及青少年胃肠疾病、肝脏疾病以及营养疾病。旗下有一本专业期刊《Journal of Pediatric Gastroenterology and Nutrition》。, copyright=0, guiderPublishedTime=Tue Apr 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年4月，北美小儿胃肠病、肝脏病和营养学会(NASPGHAN)发布了关于确保儿童炎症性肠病非住院患者生物制剂输注质量的临床报告，文章主要目的是针对家庭和门诊输注生物药剂治疗的儿童炎症性肠病患者提供8条指导建议，从而确保治疗效果。 </P> <P> </P>拓展指南：<strong>与<font color=red>炎症性肠病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=97c881c0015ea403" title="2018 ESPGHAN意见书：儿童炎症性肠病患者的营养管理" target=_blank>2018 ESPGHAN意见书：儿童炎症性肠病患者的营养管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=597961c001558037" title="2018 JSGE循证临床实践指南：炎症性肠病" target=_blank>2018 JSGE循证临床实践指南：炎症性肠病</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=8d85c1c001510111" title="2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理" target=_blank>2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ab8d41c0015100be" title="2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估" target=_blank>2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9ef291c001509341" title="2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测" target=_blank>2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%82%8E%E7%97%87%E6%80%A7%E8%82%A0%E7%97%85" target=_blank>有关炎症性肠病更多指南</a></ul>, tagList=[TagDto(tagId=1125, tagName=炎症性肠病), TagDto(tagId=7197, tagName=生物制剂)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5078, appHits=109, showAppHits=0, pcHits=3742, showPcHits=1600, likes=157, shares=7, comments=15, approvalStatus=1, publishedTime=Sun Apr 22 23:05:45 CST 2018, publishedTimeString=2018-04-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 22 23:05:45 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 19:15:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量)])
2018 NASPGHAN临床报告：确保儿童炎症性肠病非住院患者生物制剂输注质量
下载请点击：
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=316039, encodeId=f4973160395d, content=学习啦.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:24:03 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309277, encodeId=e5633092e715, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Apr 26 00:58:14 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308730, encodeId=93a3308e306e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Apr 24 06:55:51 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308469, encodeId=4d0b3084699e, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Apr 23 08:40:20 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308458, encodeId=630e3084589f, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Apr 23 08:10:55 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-05-17 1871f9015am

    学习啦.谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=316039, encodeId=f4973160395d, content=学习啦.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:24:03 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309277, encodeId=e5633092e715, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Apr 26 00:58:14 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308730, encodeId=93a3308e306e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Apr 24 06:55:51 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308469, encodeId=4d0b3084699e, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Apr 23 08:40:20 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308458, encodeId=630e3084589f, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Apr 23 08:10:55 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-26 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=316039, encodeId=f4973160395d, content=学习啦.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:24:03 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309277, encodeId=e5633092e715, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Apr 26 00:58:14 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308730, encodeId=93a3308e306e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Apr 24 06:55:51 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308469, encodeId=4d0b3084699e, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Apr 23 08:40:20 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308458, encodeId=630e3084589f, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Apr 23 08:10:55 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-24 1e1c07bdm01(暂无匿称)

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=316039, encodeId=f4973160395d, content=学习啦.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:24:03 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309277, encodeId=e5633092e715, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Apr 26 00:58:14 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308730, encodeId=93a3308e306e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Apr 24 06:55:51 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308469, encodeId=4d0b3084699e, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Apr 23 08:40:20 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308458, encodeId=630e3084589f, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Apr 23 08:10:55 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-23 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=316039, encodeId=f4973160395d, content=学习啦.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:24:03 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309277, encodeId=e5633092e715, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Apr 26 00:58:14 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308730, encodeId=93a3308e306e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Apr 24 06:55:51 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308469, encodeId=4d0b3084699e, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Apr 23 08:40:20 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308458, encodeId=630e3084589f, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Mon Apr 23 08:10:55 CST 2018, time=2018-04-23, status=1, ipAttribution=)]
    2018-04-23 龙胆草

    学习谢谢分享

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 ACG临床指南：成人克罗恩病的管理

美国胃肠病学院(ACG,American College of Gastroenterology) · 2018-03-27

2018 ESPGHAN意见书：儿童炎症性肠病患者的营养管理

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2018-03-20

2018 JSGE循证临床实践指南：炎症性肠病

日本皮肤病协会(JDA,Japanese Dermatological Association) · 2018-02-10

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理

亚洲克罗恩病和结肠炎组织(AOCC,Asian Organization for Crohn’s and Colitis) · 2017-10-10

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估

亚洲克罗恩病和结肠炎组织(AOCC,Asian Organization for Crohn’s and Colitis) · 2017-10-10

2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测

国外消化科相关专家小组（统称） · 2017-10-13